Federated Hermes Inc. Lowers Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Federated Hermes Inc. decreased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 25.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 380,418 shares of the biotechnology company's stock after selling 128,418 shares during the period. Federated Hermes Inc. owned approximately 0.40% of Sarepta Therapeutics worth $46,255,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Manchester Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after buying an additional 156 shares during the period. Sunbelt Securities Inc. lifted its position in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the period. Newbridge Financial Services Group Inc. bought a new position in Sarepta Therapeutics during the fourth quarter worth $36,000. Finally, Steward Partners Investment Advisory LLC grew its holdings in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the period. Institutional investors own 86.68% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft decreased their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. HC Wainwright raised shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price objective for the company in a research report on Wednesday, April 2nd. Needham & Company LLC dropped their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a research report on Thursday, April 3rd. Finally, Royal Bank of Canada downgraded Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $161.83.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded up $0.72 on Friday, reaching $51.03. The stock had a trading volume of 4,036,516 shares, compared to its average volume of 1,388,865. The business's 50 day moving average is $88.11 and its two-hundred day moving average is $110.10. The company has a market cap of $4.95 billion, a P/E ratio of 40.82 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 1 year low of $48.01 and a 1 year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.